



Keeping an Eye on Projected Market Moving Events in the Oncology Pipeline

OBR Radar is a snapshot of upcoming pivotal events in the oncology industry which may impact stock prices or make headlines in the media. Such events include FDA action dates, anticipated announcement of pivot-

al clinical data, and ODAC dates. Visit our website at www.oncbiz.com/radar.php to see more upcoming oncology events.

Table 1. Upcoming Market Moving Events

Date	Company	Product	Event
Q2 '10	Allos Therapeutics	Folotyn™ (pralatrexate)	Top-line results from a Phase 2b non-small cell lung cancer trial are expected in the second quarter of 2010. The study's data could potentially expand Folotyn's recently approved blood cancer indication for peripheral T-cell lymphoma (PTCL) to larger, solid tumor indications.
Q2 '10	Ariad Inc. / Merck & Co	ridaforolimus	A second interim efficacy analysis of the Phase 3 SUCCEED trial of oral ridaforolimus in patients with metastatic sarcomas who have had a favorable response to chemotherapy is expected in the second quarter of 2010. Final analysis of the progression-free survival (PFS) data, the trial's primary endpoint, is expected in the fourth quarter of 2010. Ariad and partner Merck anticipate filing for marketing approval of the investigational mTOR inhibitor in late 2010 or in 2011.
June 5, 2010	Delcath Systems	Percutaneous Hepatic Perfusion (PHP) for cancer-related liver metastases	Overall survival, a part of the secondary goals of Delcath's Phase 3 trial of its PHP system in patients with melanoma metastasizing to liver, will be presented in detail at ASCO on June 5.
June 2010	Bristol-Myers Squibb	ipilimumab	Data from BMS's first Phase 3 study (MDX-020) of ipilimumab, with a primary endpoint of overall survival (OS) and conducted in patients with previously-treated melanoma, will be presented at ASCO in June. BMS management is in discussions regarding U.S. and European biologics licensing applications (BLA) in this patient population. Phase 2 study data of ipilimumab in non-small cell lung cancer is also anticipated to be presented at ASCO. Phase 3 top-line data with ipilimumab as a first-line melanoma treatment is pending.
June 2010	Amgen	proposed brand name Prolia™ (denosumab)	Full results are expected to be released at ASCO in June '10 from a pivotal Phase 3 study of d-mab investigating whether the drug can prevent bone metastases in prostate cancer patients.
Q3 '10	Novartis AG	Tasigna® (nilotinib)	FDA accelerated approval anticipated for Novartis' Tasigna as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The FDA granted priority review for the drug on Feb. 19. If approved, Tasigna will be the first treatment for Ph+ CML patients in chronic phase since Gleevec. Data from the ENTEST Phase 3 trial showed superior efficacy for Tasigna in the first head-to-head comparison of the drug against the standard of care Gleevec in newly diagnosed Ph+ CML patients.